Meglitinides: Repaglinide or nateglinide, which stimulate insulin release, can increase the risk of low blood sugar when taken with Rybelsus
According to the SmPC, these include: Nausea usually mild to moderate and often diminishing over time Vomiting and diarrhoea which can contribute to dehydration if not managed appropriately Abdominal pain and decreased appetite reflecting the medication's effect on gastric emptying and satiety signals Constipation affecting some patients, particularly those with reduced food and fluid intake Severe gastrointestinal symptoms can lead to dehydration, which may precipitate acute kidney injury in some patients
- Liver enzymes if any preexisting liver concern, given the monkey toxicology signal
Cheryl B., 58 Tampa, FL Post-menopause was brutal
When brands invest the time to validate peptide stability early in development, they are far more likely to deliver a product that performs reliably and earns the trust of their customers